Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
Holding FR:SAN?
Track your performance easily
SAN Stock Chart & Stats
Day’s Range― - ―
52-Week Range€84.93 - €106.14
Previous CloseN/A
Volume78.83K
Average Volume (3M)1.54M
Market Cap
$122.83B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)28.4
Beta0.38
Next Earnings
Jan 30, 2025EPS Estimate
1.47Last Dividend Ex-Date
May 13, 2024Dividend Yield4.12%
Share Statistics
EPS (TTM)3.37
Shares Outstanding1,263,122,700
10 Day Avg. Volume1,370,309
30 Day Avg. Volume1,535,077
Standard Deviation0.06
R-Squared0.21
Alpha0.00629
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€109.39Price Target Upside11.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Sanofi News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsSanofi and Teva announced strong results from the Ph2b RELIEVE UCCD study, where duvakitug met its primary endpoints in ulcerative colitis and Crohn’s disease, suggesting best-in-class potential.
Market PositionData from the RELIEVE-UCCD study exceeded market expectations, positioning Sanofi and Teva for a strong presence in the large and addressable IBD market.
Pipeline And Revenue PotentialSAN FP’s 'big three' pipeline candidates could each generate over €5B in peak sales, signaling significant potential for future revenue growth.
Bears Say
Debt And ProfitabilitySignificant debt included in the deal, implying Opella profits net of interest payments will be constrained in the near term.
Earnings ImpactThe sale of Opella will lead to a pro-forma business EPS dilution of 10.6% in 2024, which cannot be totally offset even with a buyback.
Product DevelopmentSanofi is 1-2 years behind Merck and 6 months to 1 year behind Roche/Roivant in the development of treatments for UC and CD.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.12% Mutual Funds
<0.01% Other Institutional Investors
72.43% Public Companies and
Individual Investors
SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €84.93 and its highest was €106.14 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $122.83B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Jan 30, 2025 which is in 12 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Oct 25, 2024. The company reported €2.86 earnings per share for the quarter, beating the consensus estimate of €2.482 by €0.378.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €3.759 which represents an annual dividend yield of 4.12%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.47.
How many shares outstanding does Sanofi have?
Sanofi has 1,263,122,700 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €2.86 in its last earnings report, beating expectations of €2.482. Following the earnings report the stock price went up 2.541%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in FR:SAN
---
Company Description
Sanofi
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
---
SAN Company Deck
---
SAN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong sales performance, driven by key products like Dupixent and successful pharma launches, leading to raised EPS guidance. However, challenges such as product exclusivity losses and regulatory impacts were noted. Overall, the positive aspects significantly outweigh the challenges.Read More>---
SAN Stock 12 Month Forecast
Average Price Target
€109.39
▲(11.76% Upside)
Technical Analysis
Best Analysts Covering SAN
1 Year
1 Year Success Rate
27/39 ratings generated profit
1 Year Average Return
+3.93%
reiterated a buy rating last month
Copying Peter Welford's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +3.93% per trade.
---